Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

Increase in external research funding is proof of confidence in UFS
2014-12-09

The university’s sourcing of research funding from external organisations has received a significant boost this year. The growth in financing received from the National Research Foundation (NRF) alone increased from R24 million in 2013 to over R50 million in 2014.

“Because tertiary institutions can no longer survive on state subsidies alone, they are increasingly looking at alternative ways of supplementing their income. Income from these sources is utilised for various programmes and projects, with strong emphasis on research,” says Dr Glen Taylor, Senior Director: Research Development at the University of the Free State (UFS).

A source which provided considerable income for the UFS was the presentation of short learning programmes. The growth in income for the learning programmes this year was more than 30% compared to the income in 2012. “Income from short learning programmes is used to support the core business of the UFS,” says Dr Taylor.

A number of major research contracts were entered into during the course of the year. The UFS, for example, serves as an agency for a research contract of USD$10.5 million awarded by the World Bank to the Southern African Development Corporation (SADC). The contract is managed by the Institute for Groundwater Studies (IGS) and involves research on the management and formation of policies on underground water sources across boundaries.

Another substantial grant is the financing received from the Water Research Commission. The money is used to conduct research on the sustainable utilisation of water, as well as ways for the better utilisation thereof for the development of communities. The grant to the UFS for successful projects amounts to R5.5 million on average per year.

The UFS also has contracts with national and international partners. We conduct research of more than R30 million on the behalf of several mining companies, such as Anglo American, BHP Billiton, Exxaro and Goldfields Ltd. “Furthermore, we also have research funding from the National Institute of Health (NIH) in the USA, the European Union and several bilateral research agreements with countries such as Brazil, China and India, as well as contracts with Sasol and the Agricultural Research Council (ARC),” says Dr Taylor.

“We have tremendous interest from several companies wishing to finance the programmes, projects and intellectual property of the UFS, which is proof that our research is recognised and makes a difference,” he says.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept